Incidence,mortality and receptor status of breast cancer in African Caribbean women: Data from the cancer registry of Guadeloupe |
| |
| Institution: | 1. Registre général des Cancers de Guadeloupe, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe;2. Service d’anatomopathologie, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe;3. Service d’Oncologie-Radiothérapie, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe;4. Service de Gynécologie-Obstétrique, Centre Hospitalier de la Basse-Terre, Guadeloupe;5. Service de Gynécologie-Obstétrique, Centre Hospitalier Universitaire de Guadeloupe, Guadeloupe;6. Institut National de la Santé et de la Recherche Médicale Inserm U1085 - IRSET, Campus Universitaire de Fouillole, Guadeloupe;1. Department of Epidemiology, Fielding School of Public Health, University of California, CA, USA;2. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;3. Division of Pediatric Hematology/Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA;1. University of Tampere, School of Health Sciences, Tampere, Finland;2. Department of Clinical Chemistry, Helsinki University Central Hospital, Finland;3. Tampere University Hospital, Department of Urology and University of Tampere, Medical School, Tampere, Finland;4. Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands;5. Sahlgrenska Academy at Göteborg University, Gothenburg, Sweden;6. Memorial Sloan-Kettering Cancer Centre, Department of Surgery and Department of Epidemiology and Biostatistics, New York, NY, USA;7. Finnish Cancer Registry, Helsinki, Finland;1. Cancer Prevention Institute of California, Fremont, CA, United States;2. Department of Health Research and Policy (Epidemiology), Stanford University School of Medicine, Stanford, CA, United States;3. Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, United States;1. Yale School of Public Health, New Haven, CT, 06520, United States;2. Yale Cancer Center, New Haven, CT, 06520, United States;3. UCSF Departments of Neurological Surgery and Epidemiology and Biostatistics, San Francisco, CA 94143, United States;4. Yale University School of Medicine, New Haven, CT 06520, United States |
| |
| Abstract: | BackgroundGeographical disparities in breast cancer incidence and outcomes are reported worldwide. Women of African descent show lower incidence, higher mortality rates and earlier age of onset. We analyzed data from the cancer registry of Guadeloupe for the period 2008–2013.MethodsWe describe breast cancer characteristics by molecular subtype, as well as estimated observed and net survival. We used Cox proportional hazard models to determine associations between cancer subtypes and death rate, adjusted for variables of interest.ResultsOverall, 1275 cases were recorded with a mean age at diagnosis of 57(±14) years. World standardized incidence and mortality were respectively 71.9/100,000 and 14.1/100,000 person-years. Age-specific incidence rates were comparable to European and US populations below the age of 45, and higher in Guadeloupean women aged between 45 and 55 years. Overall, 65.1% of patients were hormone receptor (HR)+ and 20.1% were HR-. Triple negative breast cancers (TNBC) accounted for 14% of all cases, and were more frequent in patients under 40 (21.6% vs. 13.4%, p = 0.02). Five-year net survival was 84.9% 81.4-88.6]. It was higher for HR+/Her2+ and HR+/Her2- subtypes, and lower for HR-/Her2+ and TNBC patients.ConclusionWe found high age-specific incidence rates of breast cancer in women aged 45 to 55 years, which warrants further investigation in our population. However, this population of mainly African descent had good overall survival rates, and data according to subtypes are consistent with those reported internationally. These results may suggest that poorer survival in other African descent populations may not be an inherent feature of the disease but may be amenable to improvement. |
| |
| Keywords: | Breast cancer Caribbean Incidence Hormone receptors Her2 Guadeloupe Survival |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
